The development of new uterotonic drugs typically follows several key steps: 1. Preclinical Research: Initial studies conducted in laboratories and on animals to assess efficacy and safety. 2. Clinical Trials: Phases I-III trials to evaluate the drug in humans, scrutinizing its safety, dosage, and effectiveness. 3. Regulatory Approval: Submission of trial data to regulatory bodies like the FDA or EMA for approval. 4. Post-Marketing Surveillance: Ongoing monitoring of the drugâs performance in the general population.
